These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
975 related items for PubMed ID: 14565815
21. Fondaparinux: an update on new study results. Bauersachs RM. Eur J Clin Invest; 2005 Mar; 35 Suppl 1():27-32. PubMed ID: 15701145 [Abstract] [Full Text] [Related]
22. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement. Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Muehlhofer E, Kälebo P. Thromb Res; 2007 Mar; 120(5):685-93. PubMed ID: 17292948 [Abstract] [Full Text] [Related]
23. Prevention of deep vein thrombosis in orthopedic surgery. Eichinger S, Kyrle PA. Eur J Med Res; 2004 Mar 30; 9(3):112-8. PubMed ID: 15096320 [Abstract] [Full Text] [Related]
24. Hip fracture and venous thromboembolism in the elderly. Kwong LM. J Surg Orthop Adv; 2004 Mar 30; 13(3):139-48. PubMed ID: 15559689 [Abstract] [Full Text] [Related]
25. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Turpie AG, Bauer KA, Davidson BL, Fisher WD, Gent M, Huo MH, Sinha U, Gretler DD, EXPERT Study Group. Thromb Haemost; 2009 Jan 30; 101(1):68-76. PubMed ID: 19132191 [Abstract] [Full Text] [Related]
26. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients. Kanaan AO, Silva MA, Donovan JL, Roy T, Al-Homsi AS. Clin Ther; 2007 Nov 30; 29(11):2395-405. PubMed ID: 18158080 [Abstract] [Full Text] [Related]
27. Fondaparinux: a synthetic selective factor-Xa inhibitor. Wong NN. Heart Dis; 2003 Nov 30; 5(4):295-302. PubMed ID: 12877762 [Abstract] [Full Text] [Related]
28. New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies. Turpie AG, Eriksson BI, Bauer KA, Lassen MR. Chest; 2003 Dec 30; 124(6 Suppl):371S-378S. PubMed ID: 14668420 [Abstract] [Full Text] [Related]
29. Fondaparinux: a new antithrombotic agent. Cheng JW. Clin Ther; 2002 Nov 30; 24(11):1757-69; discussion 1719. PubMed ID: 12501872 [Abstract] [Full Text] [Related]
30. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W, RECORD1 Study Group. N Engl J Med; 2008 Jun 26; 358(26):2765-75. PubMed ID: 18579811 [Abstract] [Full Text] [Related]
32. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial). Haas S, Breyer HG, Bacher HP, Fareed J, Misselwitz F, Victor N, Weber J, ECHOS Trial Group. Int Angiol; 2006 Dec 26; 25(4):335-42. PubMed ID: 17164738 [Abstract] [Full Text] [Related]